<http://schema.org/description>
"In a new study in patients with osteoarthritis (OA) of the knee, at 12 months, total femorotibial cartilage thickness loss was reduced in sprifermin (recombinant human fibroblast growth factor 18)-treated knees compared to placebo-treated knees, with effects being significant in the lateral femorotibial compartment but not in the central femorotibial compartment."^^<http://www.w3.org/2001/XMLSchema#string>
<http://medicalxpress.com/news/2014-04-sprifermin-benefit-cartilage-loss-knee.html>